ReviewActa pharmacologica Sinica2019
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.
Review in Acta pharmacologica Sinica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Peripheral endocannabinoids in major depressive disorder and alcohol use disorder: a systematic review.BMC psychiatry · 2024Pooled it
- Activity Based Anorexia as an Animal Model for Anorexia Nervosa-A Systematic Review.Frontiers in nutrition · 2019Pooled it
- Effects of acute alcohol administration on endocannabinoids and relation to subjective effects.Psychopharmacology · 2026Trial
- The effects of acute alcohol administration on circulating endocannabinoid levels in humans.Addiction biology · 2022Trial
- Brain Function Outcomes of Recent and Lifetime Cannabis Use.JAMA network open · 2025Article
- Network topology and cannabis use following two weeks of monitored abstinence: moderation of sex and patterns of use findings.Frontiers in adolescent medicine · 2025Article
- Stress and substance use disorders: risk, relapse, and treatment outcomes.The Journal of clinical investigation · 2024Review
- Resting State Brain Networks under Inverse Agonist versus Complete Knockout of the Cannabinoid Receptor 1.ACS chemical neuroscience · 2024Article
- Dysregulation of the endogenous cannabinoid system following opioid exposure.Psychiatry research · 2023Review
- Diverse Underlying Mechanisms and Sex Differences Found in Translational Models of Cannabinoids Use: Towards Validation in Human Studies.International journal of molecular sciences · 2023Article
- Cannabis self-administration in the human laboratory: a scoping review of ad libitum studies.Psychopharmacology · 2023Article
- Association of anandamide and 2-arachidonoylglycerol concentrations with clinical features and body mass index in eating disorders and obesity.European psychiatry : the journal of the Association of European Psychiatrists · 2023Article
- Biomarkers of the Endocannabinoid System in Substance Use Disorders.Biomolecules · 2022Review
- Alcohol-Endocannabinoid Interactions: Implications for Addiction-Related Behavioral Processes.Alcohol research : current reviews · 2022Review
- Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors.Frontiers in pharmacology · 2022Article
- The endocannabinoid system - current implications for drug development.Journal of internal medicine · 2021Review
- Cannabis use and cannabis use disorder.Nature reviews. Disease primers · 2021Review
- The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health.Current neuropharmacology · 2021Review
- Psychiatric Disorders and Cannabinoid Receptors.Advances in experimental medicine and biology · 2021Review
- Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.Biomolecules · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Endocannabinoid signaling is implicated in an array of psychopathologies ranging from anxiety to psychosis and addiction. In recent years, radiotracers targeting the endocannabinoid system have been used in positron emission tomography (PET) studies to determine whether individuals with psychiatric disorders display altered endocannabinoid signaling. We comprehensively reviewed PET studies examining differences in endocannabinoid signaling between individuals with psychiatric illness and healthy controls. Published studies evaluated individuals with five psychiatric disorders: cannabis use disorder, alcohol use disorder, schizophrenia, post-traumatic stress disorder, and eating disorders. Most studies employed radiotracers targeting cannabinoid receptor 1 (CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.